Outlook Therapeutics (OTLK) Misses Q3 EPS by 44c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts OTLK Hot Sheet
Join SI Premium – FREE
Outlook Therapeutics (NASDAQ: OTLK) reported Q3 EPS of ($0.44). Revenue for the quarter came in at $1.51 million.
For earnings history and earnings-related data on Outlook Therapeutics (OTLK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MFA Financial (MFA) Misses Q3 EPS by 2c
- Trump on election: it's largely true election loss was result of Iran war
- William Blair: 'Now is the time for investors to build CRCL positions'
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
